Detailed Information

Cited 36 time in webofscience Cited 41 time in scopus
Metadata Downloads

Antiviral Activity and Safety of LB80380 in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients with Lamivudine-Resistant Disease

Authors
Yuen, Man-FungHan, Kwang-HyubUm, Soon-HoYoon, Seung KewKim, Hye-RyonKim, JohnKim, Chung RyeolLai, Ching-Lung
Issue Date
Mar-2010
Publisher
WILEY
Citation
HEPATOLOGY, v.51, no.3, pp 767 - 776
Pages
10
Indexed
SCI
SCIE
SCOPUS
Journal Title
HEPATOLOGY
Volume
51
Number
3
Start Page
767
End Page
776
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15123
DOI
10.1002/hep.23462
ISSN
0270-9139
1527-3350
Abstract
We aimed to determine the antiviral activity and safety of a new nucleotide analogue, LB80380, in chronic hepatitis B (CHB) patients with lamivudine-resistant virus. Sixty-five patients with lamivudine-resistant virus were randomized to receive five ascending daily doses (30,60, 90, 150, 240 mg) of LB80380. LB80380 was given together with lamivudine for the first 4 weeks, followed by 8 weeks of LB80380 monotherapy. This was then followed by 24 weeks of adefovir. Hepatitis B virus (HBV) DNA levels, serology, liver biochemistry, and safety were monitored. The extent of the HBV DNA reduction at week 12 was dose-dependent. The mean reduction from baseline was 2.81, 3.21, 3.92, 4.16, and 4.00 log(10) copies/mL for the five ascending dose groups. The dose-proportionate effect was statistically significant (P < 0.001) with a decrease of HBV DNA levels by an average of 1.54 log(10) copies/mL for every 1-unit increase in log(10) dose of LB80380. In 93.4% of patients, HBV DNA decreased by >2 log(10) copies/ml, and 11.5% of patients had undetectable HBV DNA levels (< 300 copies/mL) by week 12. HBV DNA suppression was maintained during the 24 weeks of adefovir treatment. Hepatitis B e antigen seroconversion and normalization of alanine aminotransferase were seen in 14.6% and 24.6% of patients, respectively, at week 12; 44.6% of patients experienced mild and self-limiting adverse events, none of which were attributed to the study drug. Conclusion: LB80380 at doses of up to 240 mg is safe, well tolerated, and effective at reducing viral load in CHB patients with lamivudine-resistant virus for a period of 12 weeks. (HEPATOLOGY 2010;51:767-776.)
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE